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The introduction of technetium-99m methoxyisobu-
tylisonitrile (99mTc-MIBI) into clinical practice has
markedly improved surgeons’ ability to localize para-
thyroid adenomas before operation [1]. However, the
presence of thyroid disease with a late washout de-
creases the specificity of scintigraphy because it may
mimic a parathyroid nodule in late images. Coexisting
thyroid and parathyroid disease is found in 15–70%
of patients treated for primary hyperparathyroidism
[2]. The most frequent cause of false-positive results
in 99mTc-MIBI parathyroid imaging is a solid thyroid
nodule, either solitary or in a multinodular gland [3].
The possibility of a coincidental appearance of hyper-
parathyroidism and thyroid cancer is not often consid-
ered because of its low incidence. Here, we present a
case of parathyroid adenoma coexisting with two sites
of papillary thyroid carcinoma, which was revealed
by dual-phase 99mTc-MIBI parathyroid imaging.
CASE PRESENTATION
A 49-year-old woman without chronic renal failure
had esophagitis with presentation of anterior chest
pain. The biochemical profile performed to check for
anterior chest pain revealed increased levels of serum
calcium of 12.2 mg/dL (normal, 9.0–10.6 mg/dL) and
intact parathyroid hormone (PTH) of 130 pg/mL
(normal, 12–72 pg/mL), and a low serum phosphorus
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The possibility of a coincidental appearance of hyperparathyroidism and thyroid cancer is not
often considered because of its low incidence. Here, we present a case of a 49-year-old woman
with a parathyroid adenoma coexisting with two sites of papillary thyroid carcinoma. Dual-phase
99mTc-methoxyisobutylisonitrile (MIBI) parathyroid imaging before the operation correctly visu-
alized the site of the parathyroid adenoma. In addition, two papillary thyroid carcinomas
showed faint uptake of 99mTc-MIBI on delayed image. Total thyroidectomy and parathyroidec-
tomy of a solitary parathyroid adenoma were performed. The patient subsequently underwent
radioiodine-131 ablation and was treated with T4 suppression. This case illustrates the need for
clinical awareness of concomitant hyperparathyroidism and thyroid cancer. Dual-phase 99mTc-
MIBI parathyroid imaging may be useful for detecting indolent thyroid cancer before it becomes
a distinct disease.
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level of 2.2 mg/dL (normal, 2.5–4.5 mg/dL), consistent
with primary hyperparathyroidism.
To clarify the cause of primary hyperparathy-
roidism, dual-phase 99mTc-MIBI parathyroid imaging
was performed over the head, neck and chest using a
dual-head gamma camera with a parallel-hole colli-
mator. The early images obtained immediately after
radiotracer injection revealed an area with increased
radioactivity (greater than that in thyroid tissue) in the
right lower thyroid lobe (Figure 1). The delayed image
obtained 2 hours after injection showed persistent
activity in the right lower thyroid lobe. In addition,
faint residual radioactivity in the right upper lobe and
left lower lobe of the thyroid were noted (Figure 2).
The patient subsequently underwent parathyroid-
ectomy. During the operation, hard nodules were
palpable in the upper portion of the right thyroid
lobe and lower portion of the left thyroid lobe and
were then enucleated. The frozen section showed
papillary thyroid carcinomas. The extent of surgery
was changed to total thyroidectomy in addition to
parathyroidectomy.
The postoperative intact PTH level decreased to
25.5 pg/mL from a preoperative level of 542 pg/mL.
A B
Figure 1. 99mTc-MIBI image taken immediately after injection shows intense focal uptake in the inferior aspect of the right lobe
(arrow).
A B
Figure 2. The 2-hour delayed image shows the focal retention within a presumed right inferior parathyroid adenoma (arrow). In addition,
two areas with faint retention are present in the right upper lobe and left lower lobe (arrowheads).
Histopathology results revealed parathyroid adenoma
in the right lower parathyroid gland and papillary
carcinomas of the thyroid gland in the bilateral thy-
roid lobes. The papillary carcinoma in the right thyroid
lobe was about 1×1 cm and in the left lobe was about
1×0.5 cm. The right lower parathyroid adenoma was
1×0.5 cm and weighed 0.95 g.
The patient subsequently underwent radioiodine-
131 ablation 1 month after surgery, was treated with
T4 suppression and followed as an outpatient.
Follow-up intact PTH level of 23.8 pg/mL and thy-
roglobulin level under T4 suppression of less than
0.2 ng/mL were both acceptable at 9 months after
operation.
DISCUSSION
Taillefer et al developed a double-phase imaging pro-
cedure with 99mTc-MIBI for the detection and local-
ization of parathyroid adenomas based on the fact
that 99mTc-MIBI washes out more rapidly from the
thyroid than from abnormal parathyroid tissue [4]. 
It is simple to perform and does not require immobi-
lization of the patient or computerized analysis, which
are limitations of the dual radiotracer procedure. The
presence of a parathyroid adenoma is defined as a
focal area showing increased 99mTc-MIBI uptake in
projection of the thyroid bed and surrounding areas
or mediastinum, which shows either a relatively pro-
gressive increase over time or a fixed uptake that per-
sists on delayed imaging, contrary to the uptake in
the surrounding normal thyroid tissue, which pro-
gressively decreases over time. The sensitivity of the
dual-phase protocol is 50–86%, and is influenced 
by a variety of factors including tumoral tissue vol-
ume, oxyphilic cell content, P-glycoprotein expression,
mitochondrial structure, injected dose of radiotracer,
timing of imaging after radiotracer injection, and ac-
quisition equipment and settings [5–8]. Normal thyroid
tissue significantly accumulates 99mTc-MIBI within a
few minutes after injection and shows significant
washout 2–3 hours after injection with a half-life of
about 50 minutes [9,10].
In practice, confusion may occur if the patient has
delayed thyroid washout. 99mTc-MIBI is a lipophilic
cationic agent that localizes primarily in mitochondria
after passive diffusion into cells. Despite its nonspeci-
ficity, 99mTc-MIBI scintigraphy has been shown to
accumulate in thyroid neoplastic nodules. Thyroid car-
cinoma is found in about 3% of patients with hyper-
parathyroidism [2,11]. Rubello et al reported two cases
of parathyroid adenoma coexisting with a papillary
thyroid carcinoma shown on double-tracer MIBI
scintigraphy [12]. Caglar and Naldoken described a
case of a 55-year-old man with hyperparathyroidism
and papillary thyroid cancer found during surgery
[13]. A parathyroid adenoma was clearly shown in the
thallium-technetium subtraction parathyroid imag-
ing. However, the foci of papillary thyroid cancer
were not demonstrated in the images [13]. Boi et al
described a 62-year-old woman with two focal areas
of increased 99mTc-MIBI uptake in dual-phase scan-
ning, which were identified as a parathyroid adenoma
and a thyroid papillary carcinoma, respectively [14].
The association between thyroid carcinoma and hyper-
parathyroidism may be coincidental. Burmeister et al
compared the incidence of thyroid carcinoma among
groups of primary, secondary and tertiary hyperpara-
thyroidism patients and found that the prevalence of
thyroid carcinoma in a population of patients under-
going parathyroidectomy for hyperparathyroidism
was the same irrespective of whether the patients had
primary, secondary or tertiary hyperparathyroidism
[15]. They concluded that the detection of thyroid car-
cinoma at the time of parathyroidectomy is related to
risk factors that are probably not associated with
hyperparathyroidism.
In studies differentiating cold thyroid nodules with
dual-phase 99mTc-MIBI scintigraphy, thyroid papil-
lary carcinoma exhibits an initially increased uptake
and delayed washout. Erdil et al reported that the
delayed lesion-to-non-lesion ratio at 90 minutes after
injection of 99mTc-MIBI was superior to the early
lesion-to-non-lesion ratio at 15 minutes after injection
for the detection of malignant thyroid nodules [16].
In Demirel et al’s study of 43 patients with solitary
cold thyroid nodules, increased 99mTc-MIBI radioac-
tivity (greater than that in normal thyroid tissue) was
demonstrated in all of the patients with papillary
thyroid carcinoma on the image taken 15 minutes
after injection and all except one patient on the image
taken 120 minutes after injection [17]. More recently,
Sharma et al studied solitary thyroid nodules using
30- and 120-minute 99mTc-MIBI scans and reported
that 19 of the 22 patients with papillary carcinoma in
their study showed a 30/120-minute ratio of more
than one [18].
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In our case, the delayed images showed two sites
of radioactivity representing papillary carcinomas in
addition to the radioactivity of parathyroid adenoma.
Radioactivity of the papillary carcinomas was not evi-
dent on the early image because of the high thyroidal
radioactivity and low lesion-to-non-lesion ratio. Small
tumoral tissue volume may also be an explanation for
this phenomenon. Despite the faint 99mTc-MIBI radio-
activity in thyroid carcinomas on the delayed image,
they could be identified readily by a greater lesion-
to-background contrast in radioactivity, which may
result from a greater washout of 99mTc-MIBI from
normal thyroid tissue than from the thyroid carcinoma.
Although the incidence of thyroid malignancy in
patients with hyperparathyroidism is relatively low,
delayed thyroid clearance of 99mTc-MIBI may need to
be investigated further.
Besides the 99mTc-MIBI scan, ultrasound and mag-
netic resonance imaging (MRI) are also used for 
preoperative localization of abnormal parathyroid
glands, although they were not used in this case.
Ultrasound is a noninvasive, simple to perform, inex-
pensive and nonionizing tool that is very reliable
when carried out by an experienced operator. Ultra-
sound is effective in detecting lesions of the neck and
can guide biopsy. However, ultrasound is not helpful
in identifying ectopic mediastinal, retroesophageal
or retrotracheal parathyroid glands, and is difficult 
if the patient has had previous surgery [19,20]. In
contrast, the large scanning field of 99mTc-MIBI imag-
ing enables it to localize ectopic parathyroid glands.
In addition, there is less interference from previous 
surgery in the interpretation of 99mTc-MIBI imaging,
based on functional properties. In a recent study by
Sukan et al, the sensitivity increased from 70% and
60% for MIBI and ultrasound, respectively, to 81% 
for the combination of both methods. They concluded
that the combination MIBI and ultrasound reduces
the chance of missing concomitant thyroid pathology
that may change the treatment [21]. Moreover, MRI
can show different signal intensities of enlarged para-
thyroid glands and can perform a three-dimensional
reconstruction. MRI can be particularly helpful when
the possibility of ectopic glands is high. However,
parathyroid adenomas, hyperplasia and carcinoma
all have a similar appearance on MRI and this leads
to a lower specificity [22]. MRI is often reserved for
the evaluation of patients with hyperparathyroidism
if ultrasound and/or scintigraphy are equivocal.
In conclusion, this case illustrates the need for clin-
ical awareness of concomitant hyperparathyroidism
and thyroid cancer. Dual-phase 99mTc-MIBI parathy-
roid imaging may be useful in detecting indolent 
thyroid cancer before it becomes a distinct disease.
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雙時相鎝 99m-MIBI 副甲狀腺核醫攝影顯示
同時合併副甲狀腺腺瘤與甲狀腺乳突癌
 — 病例報告
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因發生率低，我們時常忽略同時合併副甲狀腺機能亢進和甲狀腺癌之可能性。本文報
告一位 49 歲女性同時診斷副甲狀腺腺瘤與甲狀腺乳突癌。核醫鎝 99m-MIBI 雙時相
副甲狀腺核醫攝影正確地顯示副甲狀腺腺瘤的位置。另外，兩處甲狀腺乳突癌亦於延
遲相中呈現輕度攝取。病患接受甲狀腺全切除與副甲狀腺摘除，接著接受放射碘治療
與甲狀腺素補充治療。臨床上須注意同時合併副甲狀腺機能亢進和甲狀腺癌之可能
性。核醫鎝 99m-MIBI 雙時相副甲狀腺核醫攝影或許於疾病發展明顯前能偵測隱藏的
甲狀腺癌。
關鍵詞：雙時像鎝 99m-MIBI 副甲狀腺攝影，副甲狀腺機能亢進，副甲狀腺腺瘤，甲狀腺癌
(高雄醫誌 2008;24:542–7)
